Publication: Pathological roles of platelets in inflammatory diseases: The emerging targets for new drug development
Issued Date
2021-01-01
Resource Type
ISSN
25868470
25868195
25868195
Other identifier(s)
2-s2.0-85118785166
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Sciences Asia. Vol.48, No.5 (2021), 402-412
Suggested Citation
Surasak Wichaiyo, Arnatchai Maiuthed Pathological roles of platelets in inflammatory diseases: The emerging targets for new drug development. Pharmaceutical Sciences Asia. Vol.48, No.5 (2021), 402-412. doi:10.29090/psa.2021.05.21.023 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78573
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pathological roles of platelets in inflammatory diseases: The emerging targets for new drug development
Author(s)
Other Contributor(s)
Abstract
Platelets, the cytoplasmic fragments of megakaryocytes, play a primary role in hemostasis. In addition, current evidence demonstrates the contribution of platelets in inflammation. Platelet-associated cell surface proteins (e.g. CD40L, P-selectin, GPVI and CLEC-2) and secretory molecules (e.g. PF4 and RANTES) regulate inflammatory response in various conditions, including cardio-cerebrovascular diseases, inflammatory bowel disease, rheumatoid arthritis and infection/sepsis. Anti-platelets and anti-inflammatory drugs have been shown to reduce the expression and/or function of these platelet-derived molecules, in association with the improved clinical outcomes in patients with inflammatory diseases. Moreover, the novel anti-inflammatory agents that act against platelet-specific targets have been being developed, which might be a potential therapeutic approach in thrombo-inflammatory diseases.